Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 34 n° 296

Posts Tagged ‘neuroscience’

Webinar dell’Università di Parma “Apprendimento e scelta nei disturbi affettivi”

Posted by fidest press agency su sabato, 6 febbraio 2021

Parma Martedì 9 febbraio, con inizio alle 15, si terrà il Simposio “Apprendimento e scelta nei disturbi affettivi” organizzato dal Laboratorio Neuroscience & Humanities dell’Università di Parma, diretto da Vittorio Gallese. All’incontro, che si terrà interamente in lingua inglese su piattaforma Microsoft Teams, interverranno i ricercatori Erdem Pulcu e Neil Garrett dell’Università di Oxford e Christoph Korn dell’Università di Heidelberg, che operano nel campo delle neuroscienze. L’evento è finalizzato a rafforzare le collaborazioni già in atto tra queste istituzioni e la nostra Università.Il simposio è primariamente rivolto a giovani ricercatori e PhD interessati all’argomento del decision making, le cui applicazioni spaziano dalla psicopatologia all’economia. La partecipazione è gratuita e aperta a tutti.

Posted in Cronaca/News, Università/University | Contrassegnato da tag: , , , | Leave a Comment »

5th Annual Neuroscience R&D Technologies Conference

Posted by fidest press agency su lunedì, 23 settembre 2019

Learn from 20+ industry-leading speakers who will be sharing their presentations on CNS drug discovery, Latest Optogenetic tools, kinematic techniques, Blood-Brain Barrier Proteomics, and Non-Invasive electrical brain stimulation.Improving clinical translation in neuroscience research has always been a major challenge until now. There are many research collaborations happening in the neuroscience space today for neurodegenerative disorders research. The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.Case studies presented from leading technology collaborations, Interactive panel and breakout sessions along with Access to online presentations on-demand post-summit.First-ever conference on application of technology in developing neurological treatments. Meet 100+ global heads of neuroscience from the industry and Academics.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

The Neuroscience of Autism: New Clues for How the Condition Begins

Posted by fidest press agency su giovedì, 4 luglio 2019

The discovery, published in Neuron, illuminates the molecular details of a key process in brain development and adds to the scientific understanding of the biological basis of autism spectrum disorder (ASD), a condition linked to brain development and estimated to affect about one in 59 children born in the United States.The cerebral cortex – which in humans is responsible for higher brain functions including perception, speech, long-term memory, and consciousness – is relatively large and dominant compared to other brain structuresHow the cortex constructs itself in the developing brain of a human or other mammal is far from fully understood. But scientists know that early in cortical development, precursor cells called radial glial cells (RGCs) appear at the bottom of the developing cortex in a regularly spaced or tiled pattern. Each RGC sprouts a single stalk-like structure, called a basal process that extends to the top of the cortex. Collectively these RGCs and their basal processes form a scaffold, much like the scaffolds of a construction site. RGCs divide to form young cortical neurons, and these baby neurons climb the scaffold to find their proper places in the developing brain. The cortex, thanks to this scaffolding system, normally develops a highly regular structure with six distinct layers of neurons required for the normal formation of functional neural cortical circuits.Anton and colleagues discovered that a gene encoding for a protein called Memo1 is needed to organize the tiled radial glial cell scaffold. Mutations in the Memo1 gene also have been found in some people with autism and are suspected of causing the condition. To explore Memo1’s role in brain development and autism, Anton’s team first engineered mice in which the Memo1 gene is deleted early in brain development in RGCs.
They found the resulting RGC scaffold is disrupted. Each RGC’s stalk-like basal process formed too many branches and no longer forms a guiding scaffold, resulting in neuronal misplacement and disorganized layers. The scientists traced this ill effect, in part, to unstable microtubules, which normally help reinforce the scaffold structure and serve as railways for the internal traffic of key molecules necessary for RGC function.Intriguingly, studies of the brains of children with autism found patches of similar neuronal disorganization. The scientists then analyzed MEMO1 gene mutations reported recently in individuals with autism behaviors and intellectual disabilities. They discovered the human MEMO1 genetic mutation resulted in a shortened form of the Memo1 protein and this can disrupt RGC development. Further supporting the autism connection, Anton and his colleagues discovered the mice lacking Memo1 in their RGCs behaved abnormally, showing a lack of explorative activity similar to those seen in some people with autism.The findings overall suggest that Memo1-associated autism may be wired into the brain very early in development than are other forms of autism with origins in disrupted neuronal differentiation and connectivity.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Concord Health Partners Completes Investment in MIVI Neuroscience

Posted by fidest press agency su giovedì, 16 Maggio 2019

Concord Health Partners (“Concord”), a healthcare focused investment firm, has completed an investment in MIVI Neuroscience, Inc. (“MIVI”), a medical device company that provides innovative products for neuro-interventional procedures. The investment reflects Concord’s approach of investing in healthcare companies that offer innovative and proprietary technologies with the potential to lower costs, improve outcomes and enhance the value of care.There has been significant global growth in the utilization of endovascular stroke therapy procedures since the publication of compelling data from several independent clinical trials in 2015 and 2016 that highlight the value of such techniques in clearing occlusive blood clots from large cerebral vessels. MIVI’s product portfolio provides physicians with innovative tools designed to help improve outcomes, shorten procedure times and make treatment available to potentially more patients by providing easier access to difficult to treat smaller vessels in the brain.Concord Health Partners (“Concord”) is a healthcare focused investment firm with a strategic partnership model that optimizes the alignment of interests between investors and portfolio companies. Concord is primarily focused on investing in healthcare companies that have the potential to enhance the value of care through products, services, technologies and solutions that lower costs, improve quality and/or expand access to care. Concord was formed in 2017 by Founder & Managing Partner, James Olsen, a former healthcare investment banker with Bank of America Merrill Lynch and Jefferies. In 2018, Joseph Swedish, a senior healthcare executive and former Chairman & CEO of Anthem, Inc. joined Concord as Co-Founder & Partner.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »